Anthony K. Park

1.3k total citations
23 papers, 835 citations indexed

About

Anthony K. Park is a scholar working on Oncology, Genetics and Biotechnology. According to data from OpenAlex, Anthony K. Park has authored 23 papers receiving a total of 835 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 16 papers in Genetics and 7 papers in Biotechnology. Recurrent topics in Anthony K. Park's work include CAR-T cell therapy research (19 papers), Virus-based gene therapy research (16 papers) and Cancer Research and Treatments (7 papers). Anthony K. Park is often cited by papers focused on CAR-T cell therapy research (19 papers), Virus-based gene therapy research (16 papers) and Cancer Research and Treatments (7 papers). Anthony K. Park collaborates with scholars based in United States and United Kingdom. Anthony K. Park's co-authors include Saul J. Priceman, Wen-Chung Chang, Stephen J. Forman, John P. Murad, Brook Jeang, Yuman Fong, Sang‐In Kim, Dileshni Tilakawardane, Christine E. Brown and Nanhai G. Chen and has published in prestigious journals such as PLoS ONE, Clinical Cancer Research and International Journal of Molecular Sciences.

In The Last Decade

Anthony K. Park

22 papers receiving 826 citations

Peers

Anthony K. Park
Jessica Wenthe Sweden
Meijun Zheng China
Brook Jeang United States
Anthony F. Daniyan United States
Amanda Rosewell Shaw United States
Andrea Brennan United States
Catalina Martínez Colombia
Guangna Liu China
Anna Wing United States
Cornell Allen United States
Jessica Wenthe Sweden
Anthony K. Park
Citations per year, relative to Anthony K. Park Anthony K. Park (= 1×) peers Jessica Wenthe

Countries citing papers authored by Anthony K. Park

Since Specialization
Citations

This map shows the geographic impact of Anthony K. Park's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anthony K. Park with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anthony K. Park more than expected).

Fields of papers citing papers by Anthony K. Park

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anthony K. Park. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anthony K. Park. The network helps show where Anthony K. Park may publish in the future.

Co-authorship network of co-authors of Anthony K. Park

This figure shows the co-authorship network connecting the top 25 collaborators of Anthony K. Park. A scholar is included among the top collaborators of Anthony K. Park based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anthony K. Park. Anthony K. Park is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Park, Anthony K., Isabel Monroy, Yuwei Ren, et al.. (2025). Universal off-the-shelf combination immunotherapy using oncolytic viruses to redirect T cell engagers to target solid tumors. Journal for ImmunoTherapy of Cancer. 13(8). e011051–e011051.
2.
Murad, John P., Yuwei Ren, Anthony K. Park, et al.. (2025). Solid tumour CAR-T cells engineered with fusion proteins targeting PD-L1 for localized IL-12 delivery. Nature Biomedical Engineering. 2 indexed citations
3.
Zhang, Zhifang, Annie Yang, Shyambabu Chaurasiya, et al.. (2023). Anti-Tumor Immunogenicity of the Oncolytic Virus CF33-hNIS-antiPDL1 against Ex Vivo Peritoneal Cells from Gastric Cancer Patients. International Journal of Molecular Sciences. 24(18). 14189–14189. 2 indexed citations
4.
5.
Yang, Annie, Zhifang Zhang, Shyambabu Chaurasiya, et al.. (2023). Peritoneal-directed chimeric oncolytic virus CF17 prevents malignant ascites and improves survival in gastric cancer peritoneal metastases. Molecular Therapy — Oncolytics. 31. 100734–100734. 2 indexed citations
6.
Yang, Annie, Zhifang Zhang, Shyambabu Chaurasiya, et al.. (2023). Development of the oncolytic virus, CF33, and its derivatives for peritoneal-directed treatment of gastric cancer peritoneal metastases. Journal for ImmunoTherapy of Cancer. 11(4). e006280–e006280. 11 indexed citations
7.
Kim, Sang‐In, Shyambabu Chaurasiya, Anthony K. Park, et al.. (2022). Priming stroma with a vitamin D analog to optimize viroimmunotherapy for pancreatic cancer. Molecular Therapy — Oncolytics. 24. 864–872. 7 indexed citations
8.
Murad, John P., Dileshni Tilakawardane, Anthony K. Park, et al.. (2021). Pre-conditioning modifies the TME to enhance solid tumor CAR T cell efficacy and endogenous protective immunity. Molecular Therapy. 29(7). 2335–2349. 72 indexed citations
9.
Zhang, Zhifang, Annie Yang, Shyambabu Chaurasiya, et al.. (2021). CF33-hNIS-antiPDL1 virus primes pancreatic ductal adenocarcinoma for enhanced anti-PD-L1 therapy. Cancer Gene Therapy. 29(6). 722–733. 11 indexed citations
10.
Zhang, Zhifang, Annie Yang, Shyambabu Chaurasiya, et al.. (2021). PET imaging and treatment of pancreatic cancer peritoneal carcinomatosis after subcutaneous intratumoral administration of a novel oncolytic virus, CF33-hNIS-antiPDL1. Molecular Therapy — Oncolytics. 24. 331–339. 5 indexed citations
11.
Chaurasiya, Shyambabu, Sang‐In Kim, Michael P. O’Leary, et al.. (2021). Toward comprehensive imaging of oncolytic viroimmunotherapy. Molecular Therapy — Oncolytics. 23. 303–310. 5 indexed citations
12.
Kim, Sang‐In, Anthony K. Park, Shyambabu Chaurasiya, et al.. (2020). Recombinant Orthopoxvirus Primes Colon Cancer for Checkpoint Inhibitor and Cross-Primes T Cells for Antitumor and Antiviral Immunity. Molecular Cancer Therapeutics. 20(1). 173–182. 27 indexed citations
13.
Woo, Yanghee, Zhifang Zhang, Annie Yang, et al.. (2020). Novel Chimeric Immuno-Oncolytic Virus CF33-hNIS-antiPDL1 for the Treatment of Pancreatic Cancer. Journal of the American College of Surgeons. 230(4). 709–717. 29 indexed citations
14.
Park, Anthony K., Yuman Fong, Sang‐In Kim, et al.. (2020). Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors. Science Translational Medicine. 12(559). 186 indexed citations
15.
Chaurasiya, Shyambabu, Annie Yang, Jianming Lü, et al.. (2020). Oncolytic poxvirus CF33-hNIS-ΔF14.5 favorably modulates tumor immune microenvironment and works synergistically with anti-PD-L1 antibody in a triple-negative breast cancer model. OncoImmunology. 9(1). 1729300–1729300. 29 indexed citations
16.
O’Leary, Michael P., Audrey H. Choi, Sang‐In Kim, et al.. (2018). Novel oncolytic chimeric orthopoxvirus causes regression of pancreatic cancer xenografts and exhibits abscopal effect at a single low dose. Journal of Translational Medicine. 16(1). 110–110. 34 indexed citations
17.
O’Leary, Michael P., Susanne G. Warner, Sang‐In Kim, et al.. (2018). A Novel Oncolytic Chimeric Orthopoxvirus Encoding Luciferase Enables Real-Time View of Colorectal Cancer Cell Infection. Molecular Therapy — Oncolytics. 9. 13–21. 25 indexed citations
18.
Priceman, Saul J., Ethan Gerdts, Dileshni Tilakawardane, et al.. (2017). Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer. OncoImmunology. 7(2). e1380764–e1380764. 120 indexed citations
19.
Priceman, Saul J., Dileshni Tilakawardane, Brook Jeang, et al.. (2017). Regional Delivery of Chimeric Antigen Receptor–Engineered T Cells Effectively Targets HER2+ Breast Cancer Metastasis to the Brain. Clinical Cancer Research. 24(1). 95–105. 249 indexed citations
20.
Blumstein, Gideon, et al.. (2014). Effect of Delta-9-Tetrahydrocannabinol on Mouse Resistance to Systemic Candida albicans Infection. PLoS ONE. 9(7). e103288–e103288. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jessica Wenthe Breakdown of academic impact, for papers by Meijun Zheng Breakdown of academic impact, for papers by Brook Jeang Breakdown of academic impact, for papers by Anthony F. Daniyan Breakdown of academic impact, for papers by Amanda Rosewell Shaw Breakdown of academic impact, for papers by Andrea Brennan Breakdown of academic impact, for papers by Catalina Martínez Breakdown of academic impact, for papers by Guangna Liu Breakdown of academic impact, for papers by Anna Wing Breakdown of academic impact, for papers by Cornell Allen
Rankless by CCL
2026